Over a Million Americans Are Taking Ozempic Without a Medical Diagnosis

A Drug Designed for Diabetes Is Now Something Else Entirely

A large new study suggests weight-loss drugs have quietly moved from medical tool to what one researcher calls a "big Ozempic experiment." What began as a treatment for type 2 diabetes and obesity has expanded into territory that scientists are only beginning to map — and millions of Americans are already deep inside it.

Reviewing records for more than 92 million U.S. adults, researchers found over 1.1 million people on GLP-1 medications with no documented condition — such as obesity or diabetes — that would typically qualify them for a prescription. That figure is up 15-fold from 2021 to 2025. The scale of that jump is difficult to overstate. This isn't a niche trend quietly playing out in wellness circles. It's a mass medical shift happening largely outside the traditional boundaries of clinical guidance.

Who Is Taking These Drugs — and Why

The study focused on adults without a clear FDA-approved indication for GLP-1 use, meaning they lacked a current diagnosis for either type 2 diabetes, obesity, or being overweight with a possible weight-related complication like high blood pressure, obstructive sleep apnea, or heart failure. Researchers didn't document exactly why such users were taking the drugs, but the group likely includes people who aren't obese but are looking to shed a modest amount of weight.

Beyond that, researchers are exploring all kinds of new avenues for the drugs, from endometriosis to Crohn's disease, depression, and even general longevity. Off-label weight-loss users skew younger and are predominantly commercially insured. That demographic profile matters — it suggests that access to these drugs outside traditional medical channels is, at least partly, a story about who can afford them.

The Risks No One Fully Understands Yet

One potentially troubling finding from the study is that those taking the drugs off-label were more likely to have a history of eating disorders. That's a red flag that researchers are taking seriously. Drugs that suppress appetite and dramatically alter a person's relationship with food could interact in unpredictable ways with conditions like anorexia or bulimia — and the study didn't track outcomes.

Though some people may be taking these drugs off-label for valid reasons, researchers say we're largely in the dark about the overall harms of doing so. Lead author Babak Orandi of NYU Langone Health put it plainly: "You see it all over the place. You have people describing publicly their experience with these medications, some good, some bad." Social media has become a de facto information hub for users navigating this landscape without physician guidance — a dynamic that carries its own set of risks.

An Experiment Already Underway

About 1 in 8 U.S. adults — roughly 12% — are currently taking a GLP-1 drug, double the share from 18 months earlier. That adoption rate, combined with the surge in off-label use, means the country is effectively running a large, uncoordinated clinical trial on itself. Researcher Nils Kruger of Harvard Medical School captured the uncertainty plainly: "We don't know how this will play out. It's like this big Ozempic experiment."

The study, published in the journal Obesity, doesn't argue that off-label use is inherently wrong. Medicine has a long history of drugs proving useful far beyond their original purpose. But there's a meaningful difference between a physician making a careful, informed off-label decision and a million-plus people self-directing their way onto powerful metabolic drugs based on social media buzz. As GLP-1 medications continue to proliferate — with new oral versions and expanded indications on the horizon — the question of who's monitoring all of this, and how, is only going to become more urgent.